Novo Nordisk announced the FDA’s approval of FlexPro PenMate, designed for users of Norditropin FlexPro 5 mg, 10 mg, and 15 mg pens who dislike needles and prefer them to be hidden during the injection process.
The Scottsdale, AZ facility of West Pharmaceutical Services Inc. expanded to meet increased customer demand for the SmartDose Electronic Wearable Injector.
“Expanding our manufacturing capabilities in Scottsdale – and continuing scaling up production in Israel – will enable rapid, dual sourcing to our customers and help them bring innovative new treatments to market,” says Eric Resnick, president of pharmaceutical delivery systems, proprietary products at West, in a released statement.
Hospira Inc. has received the FDA’s approval to launch bivalirudin for injection, which is a generic version of The Medicines Company’s Angiomax.
It is available in single-dose flip-top vial, and the company plans to launch a differentiated presentation of the 250-mg bivalirudin for injection in Hospira’s ADD-Vantage vial.
West Pharmaceutical Services hosted a groundbreaking ceremony in Waterford, Ireland, to mark the start of construction for the company's new pharmaceutical component manufacturing facility.
The facility will manufacture packaging components for insulin injector cartridges and other high-value packaging components for injectable drugs in order to meet increasing customer demand, according to a press release. West Pharma intends to employ approximately 150 people in engineering, production and other positions by the commencement of operations in late 2018.
Pharmaceutical group Sanofi and the Ypsomed Group announced a new project to add to its longstanding partnership. Ypsomed will begin manufacturing injection system components on an additional dedicated production line starting in late 2016.
BD (Becton, Dickinson and Company), a leading global medical technology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the first drug to be offered in the just-launched BD Simplist™ ready-to-administer, line of prefilled generic injectables. BD Simplist prefilled injectables will be commercialized and manufactured by BD Rx Inc., a wholly-owned subsidiary of BD. The first BD Simplist product BD Rx will launch is Diphenhydramine Hydrochloride Injection, USP, an injectable antihistamine.
BD Medical, a segment of BD, announced today that the BD Vystra Disposable Pen will be showcased at the 2012 Parenteral Drug Association Meeting in Las Vegas. This new self-injection pen has been designed for use with a wide range of therapies that require frequent, low-volume injections or variable dosing.
Studies suggest that as many as one-fifth to one-third of people with diabetes are hesitant or unwilling to give themselves insulin injections for reasons that include needle anxiety. Patients who reported injection-related pain or embarrassment also admitted they intentionally skipped insulin injections more often. A study by the American Association of Diabetes Educators (AADE) revealed that 47% of people with diabetes would be more likely to administer their injections regularly if a product were available that would ease the pain and discomfort of injections.
Contract manufacturer JHP Pharmaceuticals has entered into an agreement with a pharmaceutical company to produce clinical and commercial supply of an innovative injectable used in the cardiovascular setting, the company reported in a press release.
INJEX Pharma AG receives FDA clearance for the import and sale of the needle free injection technology INJEX 30 into the US Market
The FDA had registered INJEX Pharma GmbH, Berlin, and INJEX Pharma US, Miami, and given approval for the import and sale of INJEX 30 in the US market. The condition was the registration by the FDA for INJEX Pharma GmbH as manufacturer and exporter. This registration is now finalized.